Journal article icon

Journal article

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.

Abstract:

BACKGROUND: Many patients with severe asthma require regular treatment with oral glucocorticoids despite the use of high-dose inhaled therapy. However, the regular use of systemic glucocorticoids can result in serious and often irreversible adverse effects. Mepolizumab, a humanized monoclonal antibody that binds to and inactivates interleukin-5, has been shown to reduce asthma exacerbations in patients with severe eosinophilic asthma. METHODS: In a randomized, double-blind trial involving 135...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1056/nejmoa1403291

Authors


Journal:
New England journal of medicine More from this journal
Volume:
371
Issue:
13
Pages:
1189-1197
Publication date:
2014-09-01
DOI:
EISSN:
1533-4406
ISSN:
0028-4793
Language:
English
Keywords:
Pubs id:
pubs:484085
UUID:
uuid:f65de5f1-fdf9-4372-b090-5f54f037cf4f
Local pid:
pubs:484085
Source identifiers:
484085
Deposit date:
2014-09-18

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP